ArticleInternal medicine (Tokyo, Japan)2023
A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer.
Naohiro Okano et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.